Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Radiation Oncology
Published in: Journal of Radiation Oncology 1/2019

01-03-2019 | NSCLC | Review

Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer

Authors: Guler Yavas, Cagdas Yavas

Published in: Journal of Radiation Oncology | Issue 1/2019

Login to get access

Abstract

Introduction

In recent years, there has been undoubted progress in the evaluation and development of targeted agents for non-small cell lung cancer (NSCLC). At the same time, remarkable progress in radiation therapy (RT) has been developed largely due to our ability to more effectively focus and deliver radiation to the tumor target volume. Both developments brought the idea of combining the radiation with molecularly targeted agents in order to improve outcomes in NSCLC patients who have limited survival times with standard chemoradiotherapy.

Methods

We identified patients with gastric cancer treated with post-operative radiation at our institution between 2002 and 2016. Acute and late toxicities were evaluated per RTOG/EORTC Radiation Toxicity Grading Scale. Statistical analysis was performed using Chi-square tests, t tests, log-rank, and logistic regression.

Results

Cetuximab has no survival benefit, and it seems to be toxic in this patient population. Bevacizumab has severe toxicity including tracheoesophageal fistulae formation in addition to its ineffectiveness. It is difficult to have an opinion about TKIs when combined with RT since most of the studies were conducted on unselected patients. For oligometastatic/oligoprogressive NSCLC patients, it seems to be reasonable to use a combined regimen since combined regimen resulted in superior survival time; however, the patients should be followed up closely with respect to the toxicity. In patients with brain metastases, the use of concomitant RT + TKIs increased survival with acceptable toxicity levels.

Conclusions

In this review, we summarize the recent literature about the use of molecularly targeted agents with concurrent RT in NSCLC patients.
Literature
1.
2.
Koh PK, Faivre-Finn C, Blackhall FH, De Ruysscher D (2012) Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treat Rev 38(6):626–640CrossRefPubMed
3.
Le Chevalier T, Arriagada R, Quoix E et al (1991) Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83(6):417–423CrossRefPubMed
4.
Groen HJ, van der Leest A, Fokkema E, Timmer PR, Nossent GD, Smit WJ, Nabers J, Hoekstra HJ, Hermans J, Otter R, van Putten J, de Vries EG, Mulder NH (2004) Continuously infused carboplatin used as radiosensitizer in locally unresectable non-small-cell lung cancer: a multicenter phase III study. Ann Oncol 15(3):427–432CrossRefPubMed
5.
Auperin A, Le Pechoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28(13):2181–2190CrossRefPubMed
6.
Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Curran W Jr, Choy H (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 16(2):187–199CrossRefPubMedPubMedCentral
7.
Perez CA, Stanley K, Rubin P et al (1980) A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 45:2744–2753CrossRefPubMed
8.
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K,Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A,Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K,Araki T (2007) Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2(7 Suppl 3):S94–S100CrossRefPubMed
9.
Steel GG (1979) Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 5:1145–1150CrossRefPubMed
10.
Bentzen SM, Harari PM, Bernier J (2007) Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 4:172–180CrossRefPubMed
11.
Blackhall F, Ranson M, Thatcher N (2006) Where next for gefitinib in patients with lung cancer? Lancet Oncol. 7(6):499–507CrossRefPubMed
12.
13.
Milas L, Fan Z, Andratschke NH, Ang KK (2004) Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies. Int J Radiat Oncol Biol Phys 58(3):966–971CrossRefPubMed
14.
Nyati MK, Morgan MA, Feng FY, Lawrence TS (2006) Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6(11):876–885CrossRefPubMed
15.
Schmidt-Ullrich RK, Mikkelsen RB, Dent P, Todd DG, Valerie K, Kavanagh BD, Contessa JN, Rorrer WK, Chen PB (1997) Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 15:1191–1197CrossRefPubMed
16.
Baumann M, Krause M, Dikomey E, Dittmann K, Dörr W, Kasten-Pisula U, Rodemann HP (2007) EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 83:238–248CrossRefPubMed
17.
Mendelsohn J (2000) Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association of Cancer Research Clinical Research Award Lecture. Clin Cancer Res 6:747–753PubMed
18.
Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, Ang K, Mendelsohn J, Fan Z (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6(2):701–708PubMed
19.
Huang SM, Bock JM, Harari PM (1999) Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935–1940PubMed
20.
Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R, Garst J, Brotherton T, Vokes EE (2011) Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 29(23):3120–3125CrossRefPubMedPubMedCentral
21.
Blumenschein GR Jr, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R (2011) Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol 29:2312–2318CrossRefPubMedPubMedCentral
22.
Bradley JD, Hu C, Komaki RU, Masters G, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco A, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Curran WJ Jr, Choy H (2017) Long-term results of RTOG 0617: a randomized phase 3 comparison of standard dose versus high dose conformal chemoradiation therapy +/− cetuximab for stage III NSCLC. Int J Radiat Oncol Biol Phys 99(2):S105CrossRef
23.
Kotsakis AR, Ramalingam SS, Tarhini AA, Heron DE, Smith R, Friedland D (2011) Multicenter phase II study of cetuximab (C) with concomitant radiotherapy (RT) followed by consolidation chemotherapy (CT) in locally advanced non-small cell lung cancer (NSCLC). J Clin Oncol 29(Suppl):abstr 7019CrossRef
24.
Jensen AD, Munter MW, Bischoff HG et al (2011) Combined treatment of non-small cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer 117(13):2986–2994CrossRefPubMed
25.
Jatoi A, Schild SE, Foster N, Henning GT, Dornfeld KJ, Flynn PJ, Fitch TR, Dakhil SR, Rowland KM, Stella PJ, Soori GS, Adjei AA (2010) A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol 21(10):2040–2044CrossRefPubMedPubMedCentral
26.
Chen YM, Pandya J, Kelly KJK et al (2011) Pilot study (SWOG S0429) of weekly cetuximab and chest radiotherapy (RT) for poor-risk stage III non-small cell lung cancer (NSCLC). J Clin Oncol 29(Suppl):abstr 7040CrossRef
27.
Hughes S, Liong J, Miah A, Ahmad S, Leslie M, Harper P, Prendiville J, Shamash J, Subramaniam R, Gaya A, Spicer J, Landau D (2008) A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thorac Oncol 3(6):648–651CrossRefPubMed
28.
Dingemans A-MB, van Baardwijk G, Reymen A et al (2011) Determination of standard dose cetuximab together with concurrent individualised, isotoxic accelerated radiotherapy and cisplatin-vinorelbine for patients with stage III non-small cell lung cancer (NSCLC): a phase I study (NCT00522886). J Thorac Oncol 6(6):abstr MO02.02
29.
30.
Ready N, Jänne PA, Bogart J, Dipetrillo T, Garst J, Graziano S, Gu L, Wang X, Green MR, Vokes EE, Cancer, Leukemia Group B, Chicago, IL (2010) Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALEB-stratified phase II trial. J Thorac Oncol 5(9):1382–1390CrossRefPubMed
31.
Niho S, Ohe Y, Ishikura S, Atagi S, Yokoyama A, Ichinose Y, Okamoto H, Takeda K, Shibata T, Tamura T, Saijo N, Fukuoka M (2012) Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402). Ann Oncol 23:2253–2258CrossRefPubMed
32.
Stinchcombe T, Socinski MA, Moore DT, Gettinger NS, Decker RH, Petty WJ et al (2011) Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). J Clin Oncol 29:457s (suppl 15; abstr 7016)CrossRef
33.
Center B, Petty WJ, Ayala D, Hinson WH, Lovato J, Capellari J, Oaks T, Miller AA, Blackstock AW (2010) A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 5(1):69–74CrossRefPubMed
34.
Rothschild S, Bucher SE, Bernier J, Aebersold DM, Zouhair A, Ries G, Lombrieser N, Lippuner T, Lütolf UM, Glanzmann C, Ciernik IF (2011) Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial. Int J Radiat Oncol Biol Phys 80(1):126–132CrossRefPubMed
35.
Okamoto I, Takahashi T, Okamoto H, Nakagawa K, Watanabe K, Nakamatsu K, Nishimura Y, Fukuoka M, Yamamoto N (2011) Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor. Lung Cancer 72(2):199–204CrossRefPubMed
36.
Levy A, Bardet E, Lacas B, Pignon JP, Adam J, Lacroix L, Artignan X, Verrelle P, Péchoux L (2017) A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget. 8(9):15924–15933CrossRefPubMed
37.
Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DHM, Crowley JJ, Gandara DR (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15):2450–2456CrossRefPubMed
38.
Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK (2015) Adding erlotinib to chemoradiation improves overall survival but not progression-free survival in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 92(2):317–324CrossRefPubMedPubMedCentral
39.
Ramella S, Trodella L, Alberti A et al (2011) Multimodality treatment with radiochemotherapy and erlotinib in advanced NSCLC (MARTE trial). J Thorac Oncol 6:Abstr MO02.04
40.
Martinez E, Martinez M, Viñolas N, Casas F, de la Torre A, Valcarcel F, Minguez J, Paredes A, Casas AP, Dómine M (2008) Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients (p) with unresectable NSCLC: a prospective randomized phase II study. J Clin Oncol 26(Supplement):7563CrossRef
41.
Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE (2008) Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 3(9):1003–1011CrossRefPubMedPubMedCentral
42.
Wan J, Cohen V, Agulnij J, Faria S, Portelance L, Ofiara L, Sultanem K, Souhami L, Hirsh V (2009) Unexpected high lung toxicity from radiation pneumonitis in a phase I/II trial of concurrent erlotinib with limited field radiation for intermediate prognosis patients with stage III or inoperable stage IIB non– small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 75(3):S110CrossRef
43.
Lilenbaum R, Samuels M, Wang X, Kong FM, Jänne PA, Masters G, Katragadda S, Hodgson L, Bogart J, Bradley J, Vokes E (2015) A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor risk stage III non-small cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). Thorac Oncol 10:143–147CrossRef
44.
Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 10:417–427CrossRefPubMed
45.
Spigel DR, Hainsworth JD, Yardley DA, Raefsky E, Patton J, Peacock N, Farley C, Burris HA 3rd, Greco FA (2010) Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 28(1):43–48CrossRefPubMed
46.
Wozniak AJ, Moon J, Thomas CR Jr, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR (2015) A pilot trial of cisplatin/etoposide/radiotherapy followed by consolidation docetaxel and the combination of bevacizumab (NSC-704865) in patients with inoperable locally advanced stage III non-small-cell lung cancer: SWOG S0533. Clin Lung Cancer 16(5):340–347CrossRefPubMedPubMedCentral
47.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, de Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368:2385–2394CrossRefPubMed
48.
Dai Y, Wei Q, Schwager C, Moustafa M, Zhou C, Lipson KE, Weichert W, J1 D, Abdollahi A (2015) Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer. Radiother Oncol 114(2):173–181
49.
Nasser H (2015) Current standards and clinical trials in systemic therapy for stage III lung cancer: what is new? ASCO Educational Book
50.
Zeng J, Baik C, Bhatia S, Mayr N, Rengan R (2014) Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncol 15:e426–e433CrossRefPubMed
51.
Couñago F, Rodríguez A, Calvo P, Luna J, Monroy JL, Taboada B, Díaz V, Rodríguez de Dios N (2017) Targeted therapy combined with radiotherapy in non-small-cell lung cancer: a review of the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society). Clin Transl Oncol 19(1):31–43CrossRefPubMed
52.
García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, Nadal E, Rodriguez-Abreu D, Viñolas N, Massuti B (2015) SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol. 17:1020–1029CrossRefPubMedPubMedCentral
53.
Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, Dowell J, Hughes R, Abdulrahman R, Camidge DR, Gaspar LE, Doebele RC, Bunn PA, Choy H, Timmerman R (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32:3824–3830CrossRefPubMed
54.
Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD (2014) Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88:892–898CrossRefPubMedPubMedCentral
55.
Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ (2013) Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thor Oncol 8:346–351CrossRef
56.
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA et al (2012) Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7:1807–1814CrossRefPubMedPubMedCentral
57.
Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S, Stahel R, Felip E, Peters S, Kerr K, Besse B, Vansteenkiste J, Eberhardt W, Edelman M, Mok T, O'Byrne K, Novello S, Bubendorf L, Marchetti A, Baas P, Reck M, Syrigos K, Paz-Ares L, Smit EF, Meldgaard P, Adjei A, Nicolson M, Crino L, van Schil P, Senan S, Faivre-Finn C, Rocco G, Veronesi G, Douillard JY, Lim E, Dooms C, Weder W, de Ruysscher D, le Pechoux C, de Leyn P, Westeel V, Panel Members (2014) 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and furtherlines in advanced disease. Ann Oncol 25:1475–1484CrossRefPubMed
58.
Luo S, Chen L, Chen X, Xie X (2015) Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases. Oncotarget. 6(18):16725–16734CrossRefPubMedPubMedCentral
59.
Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 24:1295–1304CrossRefPubMed
60.
Eichler AF, Loeffler JS (2007) Multidisciplinary management of brain metas-tases. Oncologist 12:884–898CrossRefPubMed
61.
Zhang J, Yu J, Sun X, Meng X (2014) Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from NSCLC. Cancer Lett 351:6–12CrossRefPubMed
62.
Jiang T, Min W, Li Y, Yue Z, Wu C, Zhou C (2016) Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis. Cancer Med 5(6):1055–1065CrossRefPubMedPubMedCentral
Metadata
Title
Targeted therapy combined with thoracic radiotherapy for non-small cell lung cancer
Authors
Guler Yavas
Cagdas Yavas
Publication date
01-03-2019
Publisher
Springer Berlin Heidelberg
Published in
Journal of Radiation Oncology / Issue 1/2019
Print ISSN: 1948-7894
Electronic ISSN: 1948-7908
DOI
https://doi.org/10.1007/s13566-019-00379-x

Other articles of this Issue 1/2019

Journal of Radiation Oncology 1/2019 Go to the issue

Original Research

Comparison of deep inspiration breath hold and free breathing technique in left breast cancer irradiation: a dosimetric evaluation in 40 patients

Letter to the Editor

Rectal wall delineation in patients with a rectal displacement device in place during prostate cancer radiotherapy

Rapid Communication

Reconstructed and real proton radiographs for image-guidance in proton beam therapy

Original Research

Radiotherapy for parotid malignancies: patterns of care and impact on overall survival

Original Research

Ventricular violation increases the risk of leptomeningeal disease in cavity-directed radiosurgery treated patients

Original Research

Five-year results of post-prostatectomy patients administered a hydrogel rectal spacer implant in conjunction with dose escalated external beam radiation therapy

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits